产品说明书
Fezagepras sodium
 |
同义名 : | Setogepram sodium;PBI-4050 sodium |
| CAS号 : | 1254472-97-3 | |
| 货号 : | A595115 | |
| 分子式 : | C13H17NaO2 | |
| 纯度 : | 98% | |
| 分子量 : | 228.263 | |
| MDL号 : | N/A | |
| 存储条件： |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 65 mg/mL(284.76 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 100 mg/mL(438.09 mM) |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | PBI-4050 acts as an agonist for GPR40 and as an antagonist or inverse agonist for GPR84. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02562573 | Type 2 Diabetes ... 展开 >> Metabolic Syndrome 收起 << | Phase 2 | Completed | - | Canada, Alberta ... 展开 >> Edmonton, Alberta, Canada 收起 << |
| NCT03184584 | Alström Syndrome | Phase 2 Phase 3 | Enrolling by invitation | September 2020 | United Kingdom ... 展开 >> University Hospitals Birmingham NHS Foundation Trus Birmingham, United Kingdom, B15 2PR 收起 << |
| NCT02739217 | Inflammation and Fibrosis ... 展开 >> Diabetes 收起 << | Phase 2 | Completed | - | United Kingdom ... 展开 >> University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom, B15 2PR 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
4.38mL 0.88mL 0.44mL |
21.90mL 4.38mL 2.19mL |
43.81mL 8.76mL 4.38mL |
